While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...

InflaRx ( ($IFRX) ) has shared an announcement. On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma ...

Please provide your email address to receive an email when new articles are posted on . A minimal important difference of 7-day pain scores was a 2-point improvement on an 11-point scale. A 2-point ...

InflaRx (IFRX) outlined multiple data analyses of the Phase 3 study for vilobelimab in pyoderma gangrenosum, which was terminated earlier this ...

Pyoderma gangrenosum was first described as an extraintestinal manifestation of inflammatory bowel disease (IBD) by Brunsting and colleagues in 1930. 1 They described painful enlarging necrotic ulcers ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Ulcerative pyoderma gangrenosum is a rare disease with ...

US Food and Drug Administration awards Fast Track designation for the treatment of ulcerative pyoderma gangrenosum Fast track follows recently reported orphan drug designation by both US FDA and EMA ...

Dear Dr. Roach: I am a 74-year-old woman who is in good health. I was diagnosed with pyoderma gangrenosum on my left leg and I was in a lot of pain. Can you tell me the cause of this rare disease?

Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie has completed a post-marketing observational study titled ‘Post ...

"Pyoderma Gangrenosum Market Insight, Epidemiology and Market Forecast - 2032"The pyoderma gangrenosum treatment market is experiencing significant expansion, driven by increasing disease awareness, ...

It is thought to affect around one in 100,000 people in the UK and US. Pyoderma gangrenosum is believed to occur as a result of a pre-existing condition such as ulcerative colitis, Crohn's disease or ...